Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
Maliazurina B. Saad(The University of Texas MD Anderson Cancer Center), Jia Wu(The University of Texas MD Anderson Cancer Center), Ruijiang Li(Peking University), David A. Jaffray(The University of Texas MD Anderson Cancer Center), Vadeerat Rinsurongkawong(The University of Texas MD Anderson Cancer Center), Joe Y. Chang(The University of Texas MD Anderson Cancer Center), Don L. Gibbons(The University of Texas MD Anderson Cancer Center), Mara B. Antonoff(The University of Texas MD Anderson Cancer Center), Xuetao Lu(The University of Texas MD Anderson Cancer Center), Brett W. Carter(The University of Texas MD Anderson Cancer Center), Marcelo V. Negrão(The University of Texas MD Anderson Cancer Center), Kang Qin(The University of Texas MD Anderson Cancer Center), Jeff Lewis(The University of Texas MD Anderson Cancer Center), Elliana Young(The University of Texas MD Anderson Cancer Center), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Lingzhi Hong(The University of Texas MD Anderson Cancer Center), Waree Rinsurongkawong(The University of Texas MD Anderson Cancer Center), Morteza Salehjahromi(The University of Texas MD Anderson Cancer Center), Joel W. Neal(Stanford Medicine), Yanyan Lou(WinnMed), Heather A. Wakelee(Palo Alto Institute), Milena Petranović(Massachusetts General Hospital), Pingjun Chen(The University of Texas MD Anderson Cancer Center), John V. Heymach(The University of Texas MD Anderson Cancer Center), Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), Ara A. Vaporciyan(The University of Texas MD Anderson Cancer Center), Rizwan Qureshi(Unknown), Percy P. Lee(City Of Hope National Medical Center), Muhammad Aminu(The University of Texas MD Anderson Cancer Center), Michael F. Gensheimer(Stanford University), Carl M. Gay(The University of Texas MD Anderson Cancer Center), Boris Sepesi(HealthONE), Tina Cascone(The University of Texas MD Anderson Cancer Center), John D. Hazle(The University of Texas MD Anderson Cancer Center), Vamsidhar Velcheti(Cleveland Clinic), Sheeba J. Sujit(The University of Texas MD Anderson Cancer Center), Qasem Al-Tashi(The University of Texas MD Anderson Cancer Center), Yasir Y. Elamin(The University of Texas MD Anderson Cancer Center), Hyun‐Sung Lee(Baylor College of Medicine), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Caroline Chung(University of California, Los Angeles), Chao Cheng(Sun Yat-sen University), Natalie I. Vokes(The University of Texas MD Anderson Cancer Center), Amy Spelman(The University of Texas MD Anderson Cancer Center), Jianjun Zhang(The University of Texas MD Anderson Cancer Center), Carol C. Wu(The University of Texas MD Anderson Cancer Center), Saumil Gandhi(The University of Texas MD Anderson Cancer Center), Xiuning Le(The University of Texas MD Anderson Cancer Center)
Cited by 108
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k